Here we demonstrate that a novel, oral ARG1/2 inhibitor, which increases L-arginine levels in the brain and restores the functionality of GAMs and NK cells, sensitizes murine gliomas to the PD-1 inhibition. This evidence concerns the gene PDCD1 and central nervous system cancer.